Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: Results from a longitudinal observational cohort

Rheumatology (United Kingdom)

Volumn 54, Issue 1, 2014, Pages 152-156

  Wallis, Dinny ^a   Thavaneswaran, Arane ^a   Haroon, Nigil ^a   Ayearst, Renise ^a   Inman, Robert D ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Ankylosing spondylitis; Axial spondyloarthritis; Biologic; Infection

Indexed keywords

ANTIBIOTIC AGENT; GLUCOCORTICOID; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; AXIAL SPONDYLOARTHRITIS; CORTICOSTEROID THERAPY; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; INFECTION; INFECTION RISK; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKIN INFECTION; SPONDYLARTHRITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84928731219     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu255     Document Type: Article

References (13)

1. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
2. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50: 124-31.
3. Curtis JR, Patkar N, Xie A et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56:1125-33.
4. Fouque-Aubert A, Jette-Paulin L, Combescure C et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 2010;69:1756-61.
5. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-24.
6. Grijalva CG, Chen L, Delzell E et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306:2331-9.
7. Rudwaleit M, Landewe R, van der Heijde D et al. The development of Assessment of Spondylo Arthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009;68:770-6.
8. Rudwaleit M, van der Heijde D, Landewe R et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
9. van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994;53:224-8.
10. Greenberg JD, Reed G, Kremer JM et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 2010;69: 380-6.
11. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
12. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 2011;70:956-60.
13. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46: 2287-93.